# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elvis Presley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML003-SYN
- Date: 2026-07-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Coleman Ashby-Nakagawa, MD
- Calendar frame: modern shifted

## Reason for visit

Establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral. **S**

## Historical basis

- Elvis Aron Presley was born in a two-room house in Tupelo, Mississippi, on January 8, 1935; his family moved to Memphis when he was 13. **D**
- He made his first record in 1953, became a national star in 1956, served in the Army in West Germany from 1958 to 1960, and by the 1970s performed long engagements in Las Vegas and toured constantly. In 1974 he played Las Vegas from January 26 to February 9, toured through much of March, including four shows in Memphis on March 16 and 17 and a recorded show there on March 20, played Lake Tahoe from May 16 to 26, toured again in mid-June, and took a few weeks off at Graceland from early July. **D**
- From October 15 to November 1, 1973, he was treated at Baptist Memorial Hospital in Memphis under an assumed name; at the 1981 trial of his physician, an internal medicine specialist who reviewed the records testified that the consulting physicians were "withdrawing him from narcotic drugs." **D**
- He had glaucoma, including an episode of acute angle-closure glaucoma in 1971, and was under the care of one ophthalmologist from 1971 on. **D**
- It was believed that he neither smoked nor drank alcohol. **D**

10 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- He is tired all the time, sleepy in the afternoon and cannot keep up the energy his shows need. **S**
- He has put on weight and feels bloated and constipated, and is self-conscious about it on stage. **S**
- He wants to stop needing so many pills without going through withdrawal or missing a show. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation **S**
- Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation **S**
- Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time **S**
- Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time **S**
- Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma **S**
- Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist **S**
- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag **S**
- Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**
- Senna 8.6 mg oral tablet, two tablets at bedtime **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1971: Glaucoma, with an acute angle-closure episode treated years earlier; under an ophthalmologist's care since **D** (CLM-0007)
- October 15, 1973: Hospital stay of about two weeks in which, by later testimony, he was withdrawn from narcotic drugs; recorded without detail **D** (CLM-0003)

## Procedures and immunizations

- 2026-07-10 to 2026-07-10: Twelve-lead electrocardiogram at the evaluation of high blood pressure readings, before any change in his medicines: sinus rhythm at 92, normal axis, no left ventricular hypertrophy, QTc 436 ms **S**


## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

Hemoglobin: 15.1 g/dL; Sodium: 139 mmol/L; Potassium: 4 mmol/L; Creatinine: 1 mg/dL; eGFR (CKD-EPI 2021): 98 mL/min/1.73 m²; Glucose: 104 mg/dL (high); Hemoglobin A1c: 5.8% (high); ALT: 72 U/L (high); AST: 52 U/L (high); GGT: 78 U/L (high); TSH: 2.1 mIU/L; Urine albumin-to-creatinine ratio: 14 mg/g{creat}; PHQ-9: 8; GAD-7: 9; DAST-10: 7; AUDIT-C: 0. All results are synthetic.

BP 154/98 mmHg; pulse 94 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 96% on room air; weight 109 kg; BMI 32.5 kg/m². All vital signs are synthetic.

## Examination

Mental status: Polite, warm and soft-spoken; a little slowed with small pupils, without slurred speech; no signs of withdrawal; candid once reassured that the visit is not about blame; Mood tired and worried; PHQ-9 8 with item 9 scored 0, GAD-7 9; no thoughts of suicide or self-harm now or in the past. Functional status: Independent in all activities; sleeps late after shows and is drowsy through the afternoon; has fallen asleep in the car as a passenger; does not drive himself at present. Epworth Sleepiness Scale 14 (excessive daytime sleepiness); STOP-Bang 6 of 8 (snoring, tiredness, observed pauses, high blood pressure, BMI above 35 not met, neck 44 cm, male); neck circumference 44 cm. Physical examination is intentionally limited. **S**

## Safety assessment

Current ideation: absent; intent: absent; plan: absent; access reviewed: yes. Disposition: Outpatient care with close follow-up. No current or past suicidal ideation. Risk factors reviewed: opioid and sedative use disorders under assessment, taking opioids with benzodiazepines, sleep apnea symptoms, firearms at home, and the stress of touring. Means safety: firearms to be stored locked and unloaded with ammunition separate; all controlled medicines in a locked box, with unused tablets from earlier prescriptions taken back to a pharmacy; seven-day supplies; naloxone at home and in the tour bag, with two people around him taught to use it. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in his phone. Safety is reviewed at every visit. This is synthetic and does not convert historical behavior into a current finding. **S**

## Assessment

1. Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings; status draft. **S**
2. Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working; status draft. **S**
3. Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided; status draft. **S**

## Plan

- Safe prescribing of controlled drugs: a brown-bag reconciliation of every medicine, a prescription drug monitoring program check before every controlled prescription, a written single-prescriber agreement with one pharmacy, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused tablets; no controlled drug stopped abruptly. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Addiction medicine consultation to make the substance use diagnoses, start medication for opioid use disorder, and plan the benzodiazepine change and taper. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**
- Overdose prevention: naloxone nasal spray at home and in the tour bag, two people around him taught to use it, no alcohol or other sedatives, and the danger of opioids with benzodiazepines and with the sleep apnea that is suspected explained. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020) **S**
- Safety: a structured safety assessment, a written safety plan, firearms locked and unloaded with ammunition separate, the 988 Suicide & Crisis Lifeline, and safety review at every visit; PHQ-9 and GAD-7 at each review. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026) **S**
- Constipation on opioids: polyethylene glycol daily with senna as needed, fluids and fiber; a peripherally acting opioid antagonist only if these fail; an abdominal radiograph only for pain, distension or vomiting. Guideline: American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation (2019); American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation (2023) **S**
- Glaucoma: latanoprost continued, his ophthalmologist kept informed of every new medicine, no phentermine, decongestant or anticholinergic sleep aid, steroids only when essential and with his ophthalmologist's knowledge, and urgent care for eye pain with halos. Guideline: Primary Open-Angle Glaucoma Preferred Practice Pattern (2020); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026) **S**
- Performing and touring: no medication change in the week before an engagement, weekly video visits while away, controlled prescriptions sent only to one named pharmacy, a written plan for missed doses, naloxone and any prescribed devices in the tour bag, and a letter he controls for venues. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**

## Guideline basis

- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (J Addict Med 2020;14(2S Suppl 1):1-91)
- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- STOP questionnaire: a tool to screen patients for obstructive sleep apnea (2008), Anesthesiology 2008;108(5):812-821
- American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation (2019), American Gastroenterological Association (Gastroenterology 2019;156(1):218-226)
- American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation (2023), AGA and ACG (Gastroenterology 2023;164(7):1086-1106)
- Primary Open-Angle Glaucoma Preferred Practice Pattern (2020), American Academy of Ophthalmology (Ophthalmology 2021;128(1):P71-P150)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026), Aether Forge
